Indaptus Therapeutics
Price & Volume
Stats
See more52W Range | $0.71-$3.10 |
Market Cap | $10.8M |
Shares Short | 38,682 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$1.70 |
News
See moreYahoo Finance • 17 days ago
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
Yahoo Finance • last year
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Yahoo Finance • last year
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study
Yahoo Finance • last year
Indaptus Therapeutics to Present at the LD Micro Main Event XVI
About
CEO | Mr. Jeffrey A. Meckler J.D. |
CFO | Mr. Nir Sassi |
Address | Three Columbus Circle, New York, NY, United States, 10019 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 7 |
